PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
HomePublicationsPCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
2019 Value in Health
Chouaid, C. | Bensimon, L. | Millier, A. | Clay, E. | Insinga, R. | Arunachalam, A. | Khandelwal, A. | Bachelot, L. | Levy, P |
Volume: 22,
Issue: ,
Pages: S458,
